

Company Registration Number - 02908933

The Charity Registration Number is :- 1040650

Bath Institute for Rheumatic Diseases

Report and Accounts

31 March 2017

Bath Institute for Rheumatic Diseases

Report and accounts for the year ended 31 March 2017

Contents

| | Page |
|--|-------------|
| Charity information | 1 |
| Trustees' Annual Report | 2 |
| Statement of directors' responsibilities | 8 |
| Accountants' report | 10 |
| <i>Funds Statements:-</i> | |
| Statement of Financial Activities | 12 |
| Statement of Financial Activities - Prior Year statement | 13 |
| Statement of total recognised gains and losses | 14 |
| Movements in funds | 15 |
| Revenue Funds | 15 |
| Income and Expenditure account | 16 |
| Summary of funds | 15 |
| Balance sheet | 17 |
| Notes to the accounts | 18 |

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

The Trustees present their Report and Accounts for the year ended 31 March 2017, which also comprises the Directors' Report required by the the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Bath Institute for Rheumatic Diseases

The charity is also known by its operating name, BIRD

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1040650

Legal structure of the charity

The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The Governing Document is dated 16 March 1994

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

2nd Floor

RNHRD, Upper Borough Walls

Bath, BA1 1RL

Telephone 01225 336363 Email Address BIRD@birdbath.org.uk Web address www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

The Trustees in office on the date the report was approved were:-

Dr ND Hall (Chair)
Mr C Johns
Mr JT Sherwin
Dr A Mackenzie
Dr R Sengupta
Dr J Pauling
Dr A Nightingale
Dr W Tillett

The Trustees in office during the year were:

The trustees who served as trustees in the reporting period were as shown above, and, if applicable, their dates of appointment or resignation during the year.

| Name | Appointed | Resigned |
|------------------|------------------|------------------|
| Dr A Nightingale | 14 October 2016 | |
| Mrs E Gawith | | 26 April 2016 |
| Mr M Humphriss | | 28 February 2017 |

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

Objects and activities of the charity

The purposes of the charity as set out in its governing document.

BIRD is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and, to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder. The terms "arthritis" and "bone and joint disease" and "rheumatism" are used in that context throughout the annual report.

The main activities undertaken in relation to those purposes during the year.

Focusing its activities in the Bath area, BIRD seeks to support research and education into many aspects of bone and joint diseases. It does this by raising money to fund research including fellowships, to provide information days for people affected by bone and joint disease, their family, friends and carers, and by organising continuing education events for health professionals.

The main activities undertaken during the year to further the charity's purpose for the public benefit.

Grants awarded:

- BIRD funded three summer studentships, as part of the Arthritis Grand Challenge in the Department of Pharmacy & Pharmacology at the University of Bath, to Kelly Blaxall, Maria Edwards and Yasmin Kafaei Shirmanesh. The Arthritis Grand Challenge aims to address key health issues and develop new therapeutic strategies by collaboration between the university and the RNHRD. The studentships are run in conjunction with the University of Bath's Department of Pharmacy & Pharmacology and colleagues at the Royal National Hospital for Rheumatic Diseases (RNHRD).
- BIRD awarded Dr John Pauling and team a research grant for work into the epidemiological study of Systemic Sclerosis and its association with Cancer in the UK using the Clinical Practice Research Datalink.
- BIRD awarded Dr Abbie Jordan a research grant to study complementary and alternative medicines use in axial Spondyloarthritis.
- BIRD awarded Prof Mark Lindsay from the University of Bath a research grant for his work on characterisation of the CD4+ and CD8+ T-cells populations in psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis using single cell sequencing.
- BIRD awarded Dr Dario Cazzola from the University of Bath a grant for his research into Ankylosing Spondylitis and Work: a biomechanics approach to inform self-management programme.

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

Education:

- BIRD supported four Arthritis Grand Challenge meetings in collaboration with the University of Bath, all meetings were hosted and chaired by Dr Phil Hamann. The meetings were attended by Clinicians and Academics in relevant fields.
- BIRD supported the fourth ARUK study day chaired by Prof Neil McHugh held at the RNHRD, Bath.
- BIRD provided admin support to SAMBa (Department of Mathematical Sciences at the University of Bath) with their two Integrated Think Tank (ITT) weeks, led by Dr Susie Douglas and Jess Ohren. ITTs are facilitated workshops in which academic, industrial, and other external commercial partner's present problems requiring research solutions, with lectures on relevant background given by experts. Students are expected to define routes to the solution of these problems, identifying the new research that will be necessary to make this possible.
- BIRD supported two South West Connective Tissue Disease Vasculitis Group Meetings, one held in Bath hosted by Dr John Pauling and the other held in Taunton hosted by Dr Cathy Laversuch.
- BIRD ran a Joint Injection Training session for local GPs led by Dr Ahmed, consultant rheumatologist at the RNHRD, using part of the grant from the Hospital Saturday Fund for hire of anatomical models.
- BIRD worked in collaboration with RNHRD on the Bath Bristol Bone Meeting chaired by Dr Tehseen Ahmed, Consultant Rheumatologist at the RNHRD. The programme included talks from Dr Rebecca Bowen, Professor Rob Coleman, Mr Serryth Colbert and Jackie Webb.
- BIRD also worked in collaboration with RNHRD on the Bath Bristol & Weston Axial Spondyloarthritis Meeting chaired by Dr Raj Sengupta, Consultant Rheumatologist at the RNHRD. The programme included talks from Dr Alison Wadeley, Ms Emily Clarke, Ms Sandi Derham, Dr Samantha Hunt, Ms Kelly Blaxall and Dr Gerald Tracey.
- BIRD set up the facilities to run a programme of PACES courses for rheumatology trainees. The programme is run by Dr Sarah Tansley and Dr Andrew Allard, RNHRD. PACES is the final part of the MRCP exam undertaken by all UK doctors training in medical specialties. It is a practical examination involving real patients to assess doctor's skills. There are usually three opportunities each year to sit the exam. Each course is a day of teaching at the RNHRD for candidates planning on sitting the exam with a focus on rheumatology scenarios.
- BIRD hosted its annual Rheumatology Afternoon with the local rheumatology consultants at the RNHRD, the afternoon provided a primary care rheumatology update for local GPs which included talks from Dr Tim Jenkinson, Dr William Tillet, Dr Raj Sengupta, Dr Sarah Tansley, Dr John Pauling, Dr Ellie Korendowych & Dr Tehseen Ahmed.

Patient and Public Engagement (PPE):

- Appointed the Director for PPE, Mel Brooke, in April 2016.
- BIRD hosted an open day for the new PPE initiative, supported by the Mayor for Bath and North East Somerset, Councillor Paul Crossley.
- BIRD ran the 'EXPECT' conference across a range of common issues and problems that people with A&CP face.
- BIRD set up a Psoriatic Arthritis Information Day, a Lupus Information Day and a Scleroderma Information Day aimed at patients and including a variety of talks from experts on clinical research and trial updates, medications, and plenty of opportunity to contribute and ask questions. Information newsletters were produced to support each day.
- Two monthly hubs set up for informal information exchange and support, one in Bath and one in Corsham.

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

Grant making policies and how these contributed to the achievement of the charity's aims and objectives during the year.

The first meeting of the Research Assessment Group (RAG) took place on 17 June 2016, operating under new terms of reference and implementing the Grant Awarding Policy. The purpose of RAG is to review and assess applications for research funding as outlined in the policy and in line with BIRD's charitable objectives.

The main achievements and performance of the charity during the year.

Total amount of grants awarded were £125,485.

Over 500 attendees at our meetings and events for consultants, clinicians and academics.

Over 250 patient attendees to our PPE information days and hubs. Developed a network with a reach of around 1000 patients, families and carers online and in our database.

Excellent feedback from attendees of our meetings, events and information days on the quality of learning and engagement.

Fundraising activities during the year.

The pipeline for grant income was improved with a significant 90 applications made to Charitable Trusts and Foundations by our longstanding freelance expert, Kate Lane.

Some need-for-donations awareness raising activity included raffles and 'flaring rose' badge sales for PPE activity. Legacies and in memoriam donations were responded to with immediate thanks.

The difference the charity's performance during the year has made to the beneficiaries of the charity.

As outlined above, BIRD has provided grants and professional development opportunities to scientific researchers and health professionals.

The new Patient and Public Engagement programme has created a wider circle of support to patients and their families and carers and led to an increased interest in participating in research and giving feedback.

The degree to which the achievements and performance during the year have benefited wider society.

The nature of scientific research is long term, so the benefit from investment in it this year is not yet tangible, however in due course the benefits will affect almost everyone because only one person in fifty escapes some form of rheumatic complaint in their lives.

All consultant, clinician and academic attendees of our meeting and events will go on to deliver benefit to their wider communities in the form of being up to date, better informed, more stimulated and more collaborative.

Patient and Public Engagement hubs support families and carers as well as patients, reaching a wider scope of society.

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

Investment performance against the investment objectives.

BIRD has invested a substantial portion of its funds derived from the sale of its former premises in a diversified portfolio of assets. The return will help ensure BIRD's continuing support for research, education and public engagement in bone and joint diseases.

Structure, governance and management of the charity

This year saw the implementation and embedding of our new structure, with the establishment of our Research Assessment Group (RAG) and Patient Liaison and Fundraising Group (PLuG) alongside the pre-existing Finance and Investment Group (FIG) all reporting into the Council of Management. Each has terms of reference and one new appointment was made following two resignations in total in this period.

Having committed itself to greater involvement in its governance by its beneficiaries, public members were appointed to BIRD's three sub groups – Frank Sweeting to RAG, Judy Coles & Judith Beresford-Smith to PLuG and Linda McHugh to FIG.

Unfortunately our long-standing Executive Director Ali Taylor suffered a change in personal circumstances leading to long term leave of absence during the period of this report, leaving the organisation in December 2016 after nine years' service. The loss of her huge knowledge and experience in the daily running of the organisation had significant impact and this was mitigated by the Administrator Fran Staples and Bookkeeper Tina Rawlings taking up increased duties and hours, with the advice and support of the Chair, Dr Nick Hall, and trustees. A new appointment has since been made. Other changes included an office move and an overhaul of the website, now offering far more information than hitherto.

The trustees' bankers and advisors

| | |
|------------|--|
| Bankers | Unity Trust Bank, 9 Brindley Place, Birmingham B1 2HB CCLA Investment Management Ltd, COIF Charity Funds, Senator House, London Royal London Asset Management, 55 Gracechurch Street, London |
| Solicitors | Mogers Drewett, 24 Queen Square, Bath BA1 2HY |

Financial review

The charity's financial position at the end of the year ended 31 March 2017

The financial position of the charity at 31 March 2017 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

| | 2017 | 2016 |
|--|------------------|------------------|
| | £ | £ |
| Net expenditure | (20,464) | (82,025) |
| Unrestricted Revenue Funds available for the general purposes of the charity | 948,783 | 885,007 |
| Designated Revenue Funds | 68,715 | 148,854 |
| Total Unrestricted Funds | 1,017,498 | 1,033,861 |
| Restricted Revenue Funds | 39,199 | 43,300 |
| Total Funds | 1,056,697 | 1,077,161 |

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

Financial review of the position at the reporting date, 31 March 2017.

The Finance Group, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.

Policies on reserves.

BIRD's reserves policy is to

- hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
- retain sufficient in investments to maintain its grant giving capacity and educational programme.

The Council of Management review the amount to be held in reserve when approving the estimated budget for each forthcoming financial year. This follows scrutiny by the Finance Group.

In the Council of Management's view, the reserves should provide BIRD with adequate financial stability. In coming to this decision the Council of Management will (where appropriate) review the following:

- cash flow and forecasts;
- existing funds and reserves;
- future income streams;
- likely future expenditure;
- relevant operational and external trends;
- major risks facing the charity; and,

an analysis of future needs, including contingencies and risks, and the potential consequences for the charity if it is unable to meet them

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Investment policy and investment objectives.

BIRD holds just under £1m in a diversified portfolio of assets, split into two funds, £491,483 managed by COIF and £486,413 managed by VOYA, the latter via the University of Bath's investment portfolio. VOYA is invested in dollar denomination and was hedged during this accounting period to protect against currency fluctuations. For 2016-17, these investments realised gains totalling £20,661. Unrealised gains for the year totalled £152,854.

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

Plans For the Future

Summary of plans for the future and the trustees' perspective of the future direction of the charity.

BIRD is committed to funding research and affording that through wise investment of its capital supported by increased fundraising activity.

BIRD will seek to strengthen the Patient and Public Engagement initiative by expanding the programme of information days, increasing the budget (and corresponding grant applications) for the promotion and delivery of the days and building administrative capacity to support the smooth running of them.

BIRD will continue its collaborative education programme with the RNHRD, University of Bath and other third parties, continuing BIRD's objectives to provide education for clinicians and other health professionals.

Longer term, BIRD will be planning for its future mindful of the current erosion of its capital base and exploring enhanced fundraising and legacy donation activity and income.

The future physical location of the organisation also requires planning, as it is likely to change in the next few years.

Details of the Independent Examiner

Mr Tom Case

Member of Chartered Accountants

20 Goodwood Way

Cepen Park South

Chippenham

Wiltshire

SN14 0SY

Statement of the Directors Trustees's Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015 (as amended by the Bulletin issued in February 2016) .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate

Bath Institute for Rheumatic Diseases

Company Registration Number - 02908933

Trustees' Annual Report for the year ended 31 March 2017

- to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 12 to 32.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015 (as amended by the Bulletin issued in February 2016) and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 21 November 2017.

Dr ND Hall
Director and Trustee

Bath Institute for Rheumatic Diseases

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2017

I report on the financial statements of the charitable company on pages 12 to 32 for the year ended 31 March 2017 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015 (as amended by the Bulletin issued in February 2016) published by the Charity Commission in England & Wales (CCEW), effective January 2015 (The SORP), under the historical cost convention and the accounting policies set out on page 18.

Respective responsibilities of the Trustees and the Independent Examiner

As described on page 8, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the charity is not subject to audit under any legal provision, or otherwise, and is eligible for independent examination, it is my responsibility to:-

- a) examine the accounts under Section 145 of the Act;
- b) follow the procedures in the General Directions given by the Charity Commission under section 145(5)(b) of the Act and;
- c) state whether particular matters have come to my attention.

Basis of Independent Examiner's Statement and scope of work undertaken

I conducted my examination in accordance with the General Directions given by the Charity Commission under section 145(5)(b) of the Act, setting out the duties of an Independent Examiner in relation to the conducting of an Independent Examination. An Independent Examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that the financial statements comply with the SORP, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries, and consequently I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the Independent Examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Bath Institute for Rheumatic Diseases

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2017

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, in connection with my examination, I can confirm that :-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with General Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no matter has come to my attention in connection with my examination which gives me reasonable cause to believe that in any material respect the requirements :-

to keep accounting records in accordance with Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

to prepare financial statements which accord with the accounting records and comply with the accounting requirements of Section 396 of the Companies Act 2006 and The Charities Act 2011 and;

have been prepared in accordance with the requirements of Section 396 of the Companies Act 2006 and with the methods and principles set out in the FRS102 Statement of Recommended Practice - Accounting and Reporting by Charities (effective January 2016)

have not been met or to which, in my opinion, attention should be drawn in my report in order to enable a proper understanding of the accounts to be reached;

Mr Tom Case - Independent Examiner

Chartered Accountants

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY

This report was signed on 21 November 2017

Bath Institute for Rheumatic Diseases

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2017, as required by the Companies Act 2006)

| | SORP Ref | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|--------------------------------------|--------------|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| Income & Endowments from: | | | | | |
| Donations & Legacies | A1 | 18,542 | 1,929 | 20,471 | 7,525 |
| Charitable activities | A2 | 25,091 | 5,386 | 30,477 | 38,650 |
| Other trading activities | A3 | 2,417 | - | 2,417 | 5,714 |
| Investments | A4 | 75 | - | 75 | 2,009 |
| Total income | A | 46,125 | 7,315 | 53,440 | 53,898 |
| Expenditure on: | | | | | |
| Raising funds | B1 | 11,152 | - | 11,152 | 13,247 |
| Charitable activities | B2 | 224,851 | 11,416 | 236,267 | 138,065 |
| Total expenditure | B | 236,003 | 11,416 | 247,419 | 151,312 |
| Net gains on investments | B4 | 173,515 | - | 173,515 | 15,389 |
| Net expenditure for the year | | (16,363) | (4,101) | (20,464) | (82,025) |
| Net income after transfers | A-B-C | (16,363) | (4,101) | (20,464) | (82,025) |
| Net movement in funds | | (16,363) | (4,101) | (20,464) | (82,025) |
| Reconciliation of funds:- | | | | | |
| Total funds brought forward | | 1,033,861 | 43,300 | 1,077,161 | 1,159,186 |
| Total funds carried forward | | 1,017,498 | 39,199 | 1,056,697 | 1,077,161 |

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.

All activities derive from continuing operations

The notes attached on pages 18 to 32 form an integral part of these accounts.

Bath Institute for Rheumatic Diseases

Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

| | SORP Ref | Prior Year | | Prior Year |
|--|-------------|--------------------|------------------|------------------|
| | | Unrestricted Funds | Restricted Funds | Total Funds |
| | | 2016 | 2016 | 2016 |
| | | £ | £ | £ |
| Income & Endowments from: | | | | |
| Donations & Legacies | A1 | 7,525 | - | 7,525 |
| Charitable activities | A2 | 33,575 | 5,075 | 38,650 |
| Other trading activities | A3 | 5,714 | - | 5,714 |
| Investments | A4 | 2,009 | - | 2,009 |
| Other | A5 | - | - | - |
| Total income | A | 48,823 | 5,075 | 53,898 |
| Expenditure on: | | | | |
| Raising funds | B1 | 13,247 | - | 13,247 |
| Charitable activities | B2 | 128,078 | 9,987 | 138,065 |
| Other | B3 | - | - | - |
| Tax on surplus on ordinary activities | B3 | - | - | - |
| Total expenditure | B | 141,325 | 9,987 | 151,312 |
| Net gains on investments | B4 | 15,389 | - | 15,389 |
| Net expenditure for the year | | (92,502) | (4,912) | (97,414) |
| Transfers between funds | C | - | - | - |
| Net income after transfers | | (77,113) | (4,912) | (82,025) |
| Other recognised gains/(losses) | | - | - | - |
| Net gains on revaluation of fixed assets | D1 | - | - | - |
| Net actuarial gains on defined pension benefit schemes | D2 | - | - | - |
| Costs of fundamental reorganisation or restructuring | D3 | - | - | - |
| Extraordinary items | D3 | - | - | - |
| Net movement in funds | | (77,113) | (4,912) | (82,025) |
| Reconciliation of funds:- | E | | | |
| Total funds brought forward | | 1,110,974 | 48,212 | 1,159,186 |
| Total funds carried forward | | 1,033,861 | 43,300 | 1,077,161 |

All activities derive from continuing operations

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement

The notes attached on pages 18 to 32 form an integral part of these accounts.

Bath Institute for Rheumatic Diseases

Statement of Total Recognised Gains and Losses for the year ended 31 March 2017

| | 2017 £ | 2016 £ |
|---|------------------|-----------------|
| Deficit for the year :- | | |
| Net excess of income over expenditure from operations before tax | (193,979) | (97,414) |
| <i>Income from operations before tax in the Statement of Financial Activities</i> | <u>(193,979)</u> | <u>(97,414)</u> |
| Realised gains on the disposal of investments | 20,661 | 17,716 |
| <i>Deficit as shown in the Income and Expenditure account</i> | <u>(173,318)</u> | <u>(79,698)</u> |
| <i>Add/(deduct) non income and expenditure items:-</i> | | |
| Unrealised gains/(losses) on investments | 152,854 | (2,327) |
| Net Movement in funds before taxation | <u>(20,464)</u> | <u>(82,025)</u> |
| Funds generated in the year as shown on Statement of Financial Activities | <u>(20,464)</u> | <u>(82,025)</u> |

Resources applied in the year ended 31 March 2017 towards fixed assets for Charity use:-

| | 2017 £ | 2016 £ |
|--|-----------------|-----------------|
| Funds generated in the year as detailed in the SOFA | (20,464) | (82,025) |
| Resources applied on functional fixed assets | - | (2,088) |
| Net resources available to fund charitable activities | <u>(20,464)</u> | <u>(84,113)</u> |

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 18 to 32 form an integral part of these accounts.

Bath Institute for Rheumatic Diseases

Movements in revenue and capital funds for the year ended 31 March 2017

Revenue accumulated funds

| | Unrestricted Funds 2017 £ | Restricted Funds 2017 £ | Total Funds 2017 £ | Last year Total Funds 2016 £ |
|--|------------------------------------|----------------------------------|-----------------------------|---------------------------------------|
| Accumulated funds brought forward | 1,033,861 | 43,300 | 1,077,161 | 1,159,186 |
| Recognised gains and losses before transfers | (16,363) | (4,101) | (20,464) | (82,025) |
| | 1,017,498 | 39,199 | 1,056,697 | 1,077,161 |
| Closing revenue funds | 1,017,498 | 39,199 | 1,056,697 | 1,077,161 |

Designated revenue funds included within the unrestricted funds above

| | Total Funds 2017 £ | Last year Total Funds 2016 £ |
|--|-----------------------------|---------------------------------------|
| At 1 April | 148,854 | 200,105 |
| Transfer (to)/from revenue accumulated funds | (80,139) | (51,251) |
| At 31 March | 68,715 | 148,854 |

The purposes for which these funds have been designated are described in Note 20 to the accounts.

Summary of funds

| | Unrestricted and Designated funds 2017 £ | Restricted Funds 2017 £ | Total Funds 2017 £ | Last Year Total Funds 2016 £ |
|---------------------------|--|----------------------------------|-----------------------------|---------------------------------------|
| Revenue accumulated funds | 948,783 | 39,199 | 987,982 | 928,307 |
| Revenue designated funds | 68,715 | - | 68,715 | 148,854 |
| Total funds | 1,017,498 | 39,199 | 1,056,697 | 1,077,161 |

The notes attached on pages 18 to 32 form an integral part of these accounts.

Bath Institute for Rheumatic Diseases

Income and Expenditure Account for the year ended 31 March 2017 as required by the Companies Act 2006

| | 2017 | 2016 |
|--|------------------|-----------------|
| | £ | £ |
| <i>Income</i> | | |
| Income from operations | 53,133 | 51,780 |
| Realised Gains on the disposal of investments | 20,661 | 17,716 |
| Gift aid donations received from subsidiary undertaking | 232 | 109 |
| Investment income | | |
| Interest receivable | 75 | 2,009 |
| Gross income in the year before exceptional items | 74,101 | 71,614 |
| Gross income in the year including exceptional items | 74,101 | 71,614 |
| <i>Expenditure</i> | | |
| Charitable expenditure, excluding depreciation and amortisation | 235,323 | 137,295 |
| Depreciation and amortisation | 944 | 770 |
| Fundraising costs | 11,152 | 13,247 |
| Realised losses on disposals of social investments which are programme related | - | - |
| Total expenditure in the year | 247,419 | 151,312 |
| Net income before tax in the financial year | (173,318) | (79,698) |
| Tax on surplus on ordinary activities | - | - |
| Net income after tax in the financial year | (173,318) | (79,698) |
| Retained surplus for the financial year | (173,318) | (79,698) |

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 18 to 32 form an integral part of these accounts.

Bath Institute for Rheumatic Diseases - Balance Sheet as at 31 March 2017

| | SORP | | 2017 | 2016 |
|---|------|-----|------------------|------------------|
| | Note | Ref | £ | £ |
| Fixed assets | | A | | |
| Tangible assets | 8 | A2 | 2,599 | 3,543 |
| Investments held as fixed assets | 9 | A4 | 977,898 | 825,044 |
| Total fixed assets | | | <u>980,497</u> | <u>828,587</u> |
| Current assets | | B | | |
| Debtors | 11 | B2 | 23,258 | 11,884 |
| Cash at bank and in hand | | B4 | 219,811 | 316,933 |
| Total current assets | | | <u>243,069</u> | <u>328,817</u> |
| Creditors: amounts falling due within one year | 12 | C1 | <u>(166,869)</u> | <u>(80,243)</u> |
| Net current assets | | | 76,200 | 248,574 |
| The total net assets of the charity | | | <u>1,056,697</u> | <u>1,077,161</u> |
| The total net assets of the charity are funded by the funds of the charity, as follows:- | | | | |
| Restricted funds | | | | |
| Restricted Revenue Funds | 17 | D2 | 39,199 | 43,300 |
| Unrestricted Funds | | | | |
| Unrestricted Revenue Funds | 17 | D3 | 948,783 | 885,007 |
| Designated Funds | | | | |
| Designated Revenue Funds | 17 | D3 | 68,715 | 148,854 |
| Total charity funds | | | <u>1,056,697</u> | <u>1,077,161</u> |

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 11.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

Dr A Mackenzie

Trustee

Approved by the board of trustees on 21 November 2017

The notes attached on pages 18 to 32 form an integral part of these accounts.

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015 (as amended by the Bulletin issued in February 2016) published by the Charity Commission in England & Wales (CCEW) ,effective January 2016, (The SORP), and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015 (as amended by the Bulletin issued in February 2016) in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The charitable activities are entirely dependent on continuing voluntary donations as well as trading revenues. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding streams. Accordingly, the Trustees have obtained forecasts and, after reviewing the financial forecasts for future periods to 31 March 2018, the Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. Other than these matters, the Trustees are not aware of any material uncertainties about the charity's ability to continue as a going concern.

Risks and future assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs.

Accounting for deferred income and income received in advance

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their useful lives.

| | |
|---------------------|-----------------------|
| Plant and machinery | 20 % reducing balance |
|---------------------|-----------------------|

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Net (deficit)/surplus before tax in the financial year

| | |
|-------------|-------------|
| 2017 | 2016 |
| £ | £ |

The net (deficit)/surplus before tax in the financial year is stated after charging:-

| | | |
|------------------------------------|-----|-----|
| Depreciation of owned fixed assets | 944 | 770 |
|------------------------------------|-----|-----|

5 Investment gains

| | Current year Unrestricted Funds 2017 £ | Current year Restricted Funds 2017 £ | Current year Total Funds 2017 £ | Prior Year Total Funds 2016 £ |
|--|--|--|--|--|
| <i>Realised gains/(losses)</i> | | | | |
| Listed investments | 20,661 | - | 20,661 | 17,716 |
| Total realised gains/(losses) | 20,661 | - | 20,661 | 17,716 |
| <i>Unrealised gains/(losses) and writing down of carrying values</i> | | | | |
| Listed investments - Unrealised | 152,854 | - | 152,854 | (2,327) |
| Total unrealised gains/(losses) etc | 152,854 | - | 152,854 | (2,327) |
| Total realised and unrealised gains | 173,515 | - | 173,515 | 15,389 |

6 Contractor costs and emoluments

| | 2017 | 2016 |
|--|---------------|---------------|
| | £ | £ |
| Gross Salaries excluding trustees and key management personnel | 46,515 | 58,746 |
| Trustees' Remuneration | - | - |
| Total salaries, wages and related costs | 46,515 | 58,746 |

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

7 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

8 Tangible fixed assets

| | Land and Buildings | Plant & Machinery | Motor Vehicles | Total |
|-------------------------|-----------------------|----------------------|-------------------|---------------|
| | £ | £ | £ | £ |
| Cost | | | | |
| At 1 April 2016 | - | 10,561 | - | 10,561 |
| At 31 March 2017 | - | 10,561 | - | 10,561 |
| Depreciation | | | | |
| At 1 April 2016 | - | 7,018 | - | 7,018 |
| Charge for the year | - | 944 | - | 944 |
| At 31 March 2017 | - | 7,962 | - | 7,962 |
| Net book value | | | | |
| At 31 March 2017 | - | 2,599 | - | 2,599 |
| At 31 March 2016 | - | 3,543 | - | 3,543 |

9 Investments held as fixed assets

| | Investments in subsidiaries | Listed investments | Other Classes of Investment | Total |
|--|--------------------------------|-----------------------|-----------------------------------|----------------|
| | £ | £ | £ | £ |
| Carrying values of investments | | | | |
| At 1 April 2016 | 2 | 825,042 | - | 825,044 |
| Revaluation at 31 March 2017 | - | 152,854 | - | 152,854 |
| At 31 March 2017 | 2 | 977,896 | - | 977,898 |
| Analysis between fair value and historical cost | | | | |
| Investments as above held at fair value | 2 | 977,896 | - | 977,898 |

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

The company holds 20% or more of the share capital of the following companies:

| Company | Shares held | | Capital and reserves | Profit (loss) for the year |
|---|-------------|-----|----------------------|----------------------------|
| | Class | % | £ | £ |
| Bath Institute for Rheumatic Diseases Trading Limited | Ordinary | 100 | 15,967 | 232 |

10 Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the two years ending 31st March 2017.

A summary of the unaudited financial statements of the subsidiary is :-

| | 2017 | 2016 |
|---|-------------------|-------------------|
| | £ | £ |
| Assets and Funds | | |
| Aggregate amount of assets | 16,283 | 16,283 |
| Aggregate amounts of liabilities | (316) | (316) |
| Aggregate amount of funds | <u>15,967</u> | <u>15,967</u> |
| Profit and Loss | | |
| Turnover net of VAT | 305 | 18 |
| Expenses net of VAT | (73) | 91 |
| Net profit for the year before tax | <u>232</u> | <u>109</u> |
| Gift Aid Payments made to holding company | (232) | (109) |
| Net profit for the year after tax and Gift Aid | <u>-</u> | <u>-</u> |

Funds retained within charitable subsidiaries

| | 2017 | 2016 |
|--|----------|----------|
| | £ | £ |
| The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:- | <u>-</u> | <u>-</u> |

Amounts owing to and from the subsidiary are shown in the notes relating to creditors and debtors.

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

11 Debtors

| | 2017 | 2016 |
|--------------------------------|---------------|---------------|
| | £ | £ |
| Trade debtors | 15,497 | 10,557 |
| Prepayments and accrued income | 7,761 | 990 |
| Other debtors | - | 337 |
| | 23,258 | 11,884 |

12 Creditors: amounts falling due within one year

| | 2017 | 2016 |
|---|----------------|---------------|
| | £ | £ |
| Trade creditors | 9,469 | 7,912 |
| Accruals | 154,889 | 69,588 |
| Amounts owed to group undertakings and undertakings in which the company has a participating interest | 2,511 | 2,743 |
| | 166,869 | 80,243 |

13 Income and Expenditure account summary

| | 2017 | 2016 |
|-----------------------------|----------------|------------------|
| | £ | £ |
| At 1 April 2016 | 1,079,488 | 1,159,186 |
| Loss after tax for the year | (173,318) | (79,698) |
| At 31 March 2017 | 906,170 | 1,079,488 |

14 Post balance sheet events

BIRD is likely to receive a further residual balance from the estate of Margaret Holt of which £11,875 has been received in 2016-17.

BIRD has been informed by Wansbroughs solicitors they have been left a legacy in the will of the late Mr Ralph Adams. BIRD's interest in the estate is estimated to be in the region of one million pounds.

15 No related party transactions

There were no transactions with related parties in the year, except with regard to transactions with subsidiaries which are fully disclosed in notes 9 and 10 above.

16 Particulars of how particular funds are represented by assets and liabilities

| <i>At 31 March 2017</i> | Unrestricted | Designated | Restricted | Total |
|--------------------------------|----------------|---------------|---------------|------------------|
| | funds | funds | funds | Funds |
| | £ | £ | £ | £ |
| Tangible Fixed Assets | 2,599 | - | - | 2,599 |
| Investments at valuation:- | | | | |
| <i>Fixed asset investments</i> | 977,898 | - | - | 977,898 |
| Current Assets | 135,155 | 68,715 | 39,199 | 243,069 |
| Current Liabilities | (166,869) | - | - | (166,869) |
| | 948,783 | 68,715 | 39,199 | 1,056,697 |

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

| At 1 April 2016 | Unrestricted funds £ | Designated funds £ | Restricted funds £ | Total Funds £ |
|----------------------------|----------------------------|--------------------------|--------------------------|---------------------|
| Tangible Fixed Assets | 3,543 | - | - | 3,543 |
| Investments at valuation:- | | | | |
| Fixed asset investments | 825,044 | - | - | 825,044 |
| Current Assets | 136,663 | 148,854 | 43,300 | 328,817 |
| Current Liabilities | (80,243) | - | - | (80,243) |
| | 885,007 | 148,854 | 43,300 | 1,077,161 |

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

| | Funds brought forward from 2016 £ | Movement in funds in 2017 £ | Transfers between funds in 2017 £ | Funds carried forward to 2018 £ |
|--|--|-----------------------------------|---|--|
| | | See Note 18 | | |
| <i>Unrestricted and designated funds:-</i> | | | | |
| Unrestricted Revenue Funds | 885,007 | (16,363) | 80,139 | 948,783 |
| Designated Revenue Funds | 148,854 | - | (80,139) | 68,715 |
| Total unrestricted and designated funds | 1,033,861 | (16,363) | - | 1,017,498 |
| <i>Restricted funds:-</i> | | | | |
| Restricted - CRPS Conference | 9,087 | (3,322) | - | 5,765 |
| Restricted - CRPS Network UK | 2,446 | (1,480) | - | 966 |
| Restricted - CRPS Patient Forum | 5 | - | - | 5 |
| Restricted - Musculo-Skeletal | 1,477 | - | - | 1,477 |
| Restricted - Bone and Joint | 16,937 | - | - | 16,937 |
| Restricted - Non comm trials | 4,540 | - | - | 4,540 |
| Restricted - Inflammation | 1,544 | - | - | 1,544 |
| Restricted - Bone Disease | 1,930 | (1,929) | - | 1 |
| Restricted - Clinical measurement | 798 | - | - | 798 |
| Restricted - Fibromyalgia | 3,789 | - | - | 3,789 |
| Restricted - AR UK | 685 | 31 | - | 716 |
| Restricted - Arthritis Grand Challenge | (164) | 247 | - | 83 |
| Restricted - Metabolic Bone Disease | 226 | 2,352 | - | 2,578 |
| Total restricted funds | 43,300 | (4,101) | - | 39,199 |
| Total charity funds | 1,077,161 | (20,464) | - | 1,056,697 |

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

18 Analysis of movements in funds over the year as shown in Note 17

| | Income | Expenditure | Other Gains & Losses | Movement in funds |
|--|---------------|------------------|----------------------------|----------------------|
| | 2017 | 2017 | 2017 | 2017 |
| | £ | £ | £ | £ |
| Unrestricted and designated funds:- | | | | |
| Unrestricted Revenue Funds | 46,125 | (236,003) | 173,515 | (16,363) |
| Restricted funds:- | | | | |
| Restricted - CRPS Conference | 1,712 | (5,034) | - | (3,322) |
| Restricted - CRPS Network UK | 1,140 | (2,620) | - | (1,480) |
| Restricted - Bone Disease | - | (1,929) | - | (1,929) |
| Restricted - AR UK | 7,486 | (7,455) | - | 31 |
| Restricted - Arthritis Grand Challenge | 300 | (53) | - | 247 |
| Restricted - Metabolic Bone Disease | 2,557 | (205) | - | 2,352 |
| | 59,320 | (253,299) | 173,515 | (20,464) |

19 Details of transfers between funds in the year as shown in Note 17

| The transfers shown in note 17 above are:- | 2017 £ |
|--|-----------|
| To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'. | 80,139 |
| To/(from) Designated Revenue Funds | (80,139) |
| Net transfers | - |

20 The purposes for which the funds as detailed in note 17 are held by the charity are:-

Unrestricted and designated funds:-

| | |
|----------------------------------|---|
| Unrestricted Revenue Funds | These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use. |
| Unrestricted Revaluation Reserve | This fund represents the unrestricted surplus arising on the revaluation of the charity's assets. |
| Designated Revenue Funds | These funds are set aside from unrestricted sources for a specific purpose or project. |
| Designated Fixed Asset Funds | The purpose of these funds is described under the accounting policy 'Accounting for capital grants and fixed asset funds'. |

Restricted funds:-

| | |
|--------------------------------|--|
| Restricted Fixed Asset Funds | The purpose of these funds is described under the accounting policy 'Accounting for capital grants and fixed asset funds'. |
| Restricted Revaluation Reserve | This fund represents the restricted surplus arising on the revaluation of the charity's assets. |
| Restricted Revenue Funds | Funds specific for this purpose |

Bath Institute for Rheumatic Diseases

Notes to the Accounts for the year ended 31 March 2017

21 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Bath Institute for Rheumatic Diseases

Detailed analysis of income and expenditure for the year ended 31 March 2017 as required by the SORP 2015

This analysis is classified by conventional nominal descriptions and not by activity.

22 Donations and Legacies

| | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|---|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| Donations and gifts from individuals | | | | |
| Small donations individually less than £1000 | 5,435 | 1,929 | 7,364 | 2,416 |
| Gift aid donation from subsidiary undertaking | 232 | - | 232 | 109 |
| Total donations and gifts from individuals | 5,667 | 1,929 | 7,596 | 2,525 |
| Legacies receivable | | | | |
| Suzan Bond | 1,000 | - | 1,000 | - |
| Margaret Holt | 11,875 | - | 11,875 | - |
| Rosalind Talbot | - | - | - | 5,000 |
| Total legacies receivable | 12,875 | - | 12,875 | 5,000 |
| Total Donations and Legacies A1 | 18,542 | 1,929 | 20,471 | 7,525 |

23 Income from charitable activities - Trading Activities

| | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|--|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| Primary purpose and ancillary trading | | | | |
| Research and education income | 1,955 | 9,427 | 11,382 | 8,272 |
| Other income and recharged expenditure | 9,711 | (4,041) | 5,670 | 4,030 |
| Service charges - BGPRT | 13,425 | - | 13,425 | 26,348 |
| Total Primary purpose and ancillary trading | 25,091 | 5,386 | 30,477 | 38,650 |

Bath Institute for Rheumatic Diseases

Detailed analysis of income and expenditure for the year ended 31 March 2017 as required by the SORP 2015

24 Total Income from charitable activities

| | | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|---|-----------|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | | £ 2017 | £ 2017 | £ 2017 | £ 2016 |
| Total income from charitable trading | | 25,091 | 5,386 | 30,477 | 38,650 |
| Total from charitable activities | A2 | 25,091 | 5,386 | 30,477 | 38,650 |

25 Income from other, non charitable, trading activities

| | | 2017 Current year Unrestricted Funds | 2017 Current year Restricted Funds | 2017 Current year Total Funds | 2016 Prior Year Total Funds |
|------------------------------------|-----------|--|--|-------------------------------------|-----------------------------------|
| | | £ 2017 | £ 2017 | £ 2017 | £ 2016 |
| Fundraising activities | | 2,417 | - | 2,417 | 5,714 |
| Total from other activities | A3 | 2,417 | - | 2,417 | 5,714 |

26 Investment income

| | | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|--------------------------------|-----------|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | | £ 2017 | £ 2017 | £ 2017 | £ 2016 |
| Bank Interest Receivable | | 75 | - | 75 | 2,009 |
| Total investment income | A4 | 75 | - | 75 | 2,009 |

27 Expenditure on charitable activities - Direct spending

| | | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|--|--|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | | £ 2017 | £ 2017 | £ 2017 | £ 2016 |
| Gross wages and salaries - charitable activities | | 19,614 | - | 19,614 | 15,169 |
| Education expenses | | (647) | 10,868 | 10,221 | 7,743 |

Bath Institute for Rheumatic Diseases

Detailed analysis of income and expenditure for the year ended 31 March 2017 as required by the SORP 2015

| | | | | | |
|---|------------|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| Travel and conferences | | 460 | - | 460 | - |
| Repairs and maintenance of equipment | | - | - | - | 79 |
| Registration and licensing | | 813 | 493 | 1,306 | - |
| Patient public engagements | | 37,023 | - | 37,023 | 1,539 |
| Total direct spending | B2a | 57,263 | 11,361 | 68,624 | 24,530 |
| 28 Expenditure on charitable activities - Charitable trading | | | | | |
| | | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
| | | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| <i>Reallocated from support costs</i> | | 42,103 | 55 | 42,158 | 54,023 |
| Total charitable trading costs | B2b | 42,103 | 55 | 42,158 | 54,023 |
| 29 Expenditure on charitable activities- Grant funding of activities | | | | | |
| | | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
| | | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| Grants made to individuals | | 125,485 | - | 125,485 | 59,512 |
| Total grantmaking costs | B2c | 125,485 | - | 125,485 | 59,512 |
| 30 Support costs for charitable activities | | | | | |
| | | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
| | | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| <i>Employee costs not included in direct costs</i> | | | | | |
| Salaries - Administrative staff | | 26,901 | - | 26,901 | 43,577 |
| <i>Premises Expenses</i> | | | | | |
| Rent payable under operating leases | | 4,500 | - | 4,500 | 175 |
| <i>Administrative overheads</i> | | | | | |
| Telephone and internet | | 530 | - | 530 | 691 |
| Stationery, printing and postage | | 2,098 | - | 2,098 | 1,774 |
| IT support costs | | 2,462 | - | 2,462 | 2,061 |
| Insurance | | 479 | - | 479 | 490 |
| Sundry expenses | | 1,595 | - | 1,595 | 565 |

Bath Institute for Rheumatic Diseases

Detailed analysis of income and expenditure for the year ended 31 March 2017 as required by the SORP 2015

Professional fees paid to the Auditor or Independent Examiner in addition to audit and examination fees

| | | | | |
|------------------------|-----|---|-----|-----|
| As detailed in Note 31 | 360 | - | 360 | 473 |
|------------------------|-----|---|-----|-----|

Professional fees paid to advisors other than the auditor or examiner

| | | | | |
|---|-------|---|-------|-------|
| Accountancy fees other than examination or audit fees | 2,104 | - | 2,104 | 2,743 |
| Legal fees | 26 | - | 26 | 196 |

Financial costs

| | | | | |
|--|-----|----|-----|-----|
| Bank charges | 104 | 55 | 159 | 508 |
| Depreciation & Amortisation in total for | 944 | - | 944 | 770 |

| | | | | |
|--|---------------|-----------|---------------|---------------|
| Support costs before reallocation | 42,103 | 55 | 42,158 | 54,023 |
|--|---------------|-----------|---------------|---------------|

Less support costs reallocated to specific activities

| | | | | |
|-----------------------------|----------|------|----------|----------|
| To charitable trading costs | (42,103) | (55) | (42,158) | (54,023) |
|-----------------------------|----------|------|----------|----------|

| | | | | |
|----------------------------|----------|----------|----------|----------|
| Total support costs | - | - | - | - |
|----------------------------|----------|----------|----------|----------|

The basis of allocation of costs between activities is described under accounting policies

31 Other Expenditure - Governance costs

| | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|--|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| <i>Professional fees paid to the Auditor or Independent Examiner in addition to audit and examination fees</i> | | | 2017 £ | 2016 £ |
| Fees paid to the examiner's firm | 360 | - | 360 | 473 |
| Total additional fees included in support costs at Note 30 | 360 | - | 360 | 473 |

32 Total Charitable expenditure

| | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|--------------------------------|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| Total direct spending | B2a 57,263 | 11,361 | 68,624 | 24,530 |
| Total charitable trading costs | B2b 42,103 | 55 | 42,158 | 54,023 |

Bath Institute for Rheumatic Diseases

Detailed analysis of income and expenditure for the year ended 31 March 2017 as required by the SORP 2015

| | | | | | |
|-------------------------------------|------------|----------------|---------------|----------------|----------------|
| Total grantmaking costs | B2c | 125,485 | - | 125,485 | 59,512 |
| Total support costs | B2d | - | - | - | - |
| Total charitable expenditure | B2 | 224,851 | 11,416 | 236,267 | 138,065 |

33 Expenditure on raising funds and costs of investment management

| | Current year Unrestricted Funds | Current year Restricted Funds | Current year Total Funds | Prior Year Total Funds |
|--------------------------------|------------------------------------|----------------------------------|-----------------------------|---------------------------|
| | 2017 £ | 2017 £ | 2017 £ | 2016 £ |
| Cost of fundraising activities | 11,152 | - | 11,152 | 13,247 |
| Total fundraising costs | 11,152 | - | 11,152 | 13,247 |